HomeCompareAIABF vs PFE

AIABF vs PFE: Dividend Comparison 2026

AIABF yields 1538.46% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AIABF wins by $883991768.06M in total portfolio value
10 years
AIABF
AIABF
● Live price
1538.46%
Share price
$0.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$883991768.11M
Annual income
$783,774,560,703,885.50
Full AIABF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AIABF vs PFE

📍 AIABF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIABFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIABF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIABF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIABF
Annual income on $10K today (after 15% tax)
$130,769.23/yr
After 10yr DRIP, annual income (after tax)
$666,208,376,598,302.60/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AIABF beats the other by $666,208,376,575,982.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIABF + PFE for your $10,000?

AIABF: 50%PFE: 50%
100% PFE50/50100% AIABF
Portfolio after 10yr
$441995884.08M
Annual income
$391,887,280,365,072.10/yr
Blended yield
88.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AIABF
No analyst data
Altman Z
-0.7
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIABF buys
0
PFE buys
0
No recent congressional trades found for AIABF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIABFPFE
Forward yield1538.46%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$883991768.11M$49.6K
Annual income after 10y$783,774,560,703,885.50$26,258.71
Total dividends collected$876714122.30M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AIABF vs PFE ($10,000, DRIP)

YearAIABF PortfolioAIABF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$164,546$153,846.15$9,153$693.39+$155.4KAIABF
2$2,541,933$2,365,868.50$8,593$849.25+$2.53MAIABF
3$36,877,139$34,157,271.11$8,336$1,066.78+$36.87MAIABF
4$502,577,470$463,118,930.88$8,437$1,384.80+$502.57MAIABF
5$6,436,433,977$5,898,676,084.35$9,013$1,875.40+$6436.42MAIABF
6$77,488,345,446$70,601,361,090.44$10,306$2,680.72+$77488.34MAIABF
7$877,278,013,079$794,365,483,451.57$12,820$4,101.38+$877278.00MAIABF
8$9,343,682,184,854$8,404,994,710,859.21$17,673$6,826.70+$9343682.17MAIABF
9$93,660,941,503,130$83,663,201,565,336.92$27,543$12,591.86+$93660941.48MAIABF
10$883,991,768,112,235$783,774,560,703,885.50$49,560$26,258.71+$883991768.06MAIABF

AIABF vs PFE: Complete Analysis 2026

AIABFStock

Capital A Berhad, an investment holding company, provides air transportation services in Malaysia, Indonesia, the Philippines, and internationally under the AirAsia brand. It also offers management, engineering, tour operating, aircraft leasing, shared and outsourcing, central depository, financial and other related, event ticketing, and consultancy services, as well as services in the areas of information technology design, development, and implementation; facilitates business transactions for AirAsia Group with non-resident goods and service providers; and trades in coffee and tea related products, and multimedia content and equipment. In addition, the company provides inflight meal products; manages customer loyalty points; wholesales meat, fish, fruits, vegetables, flowers, and plants; offers online retail sales, inflight magazine content, inflight shop, aviation and commercial, airport related, food and beverages, and research and development services, as well as supporting services to air transport; and operates AirAsia Superapp. Further, it is involved in the marketing and development of loyalty programs; development of software for cybersecurity; and provision of media content, e-hailing, online food ordering, delivery, investment management, and cargo services, as well as provides logistic and payment services for cross border e-commerce marketing. The company was formerly known as AirAsia Group Berhad and changed its name to Capital A Berhad in January 2022. Capital A Berhad was founded in 2001 and is headquartered in Kuala Lumpur, Malaysia.

Full AIABF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AIABF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIABF vs SCHDAIABF vs JEPIAIABF vs OAIABF vs KOAIABF vs MAINAIABF vs JNJAIABF vs MRKAIABF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.